Metoclopramide Articles
Salix falls into loss on generic competition
23 March 2009
Salix to provide REMS for Metozolv
9 March 2009
FDA orders boxed warning on metaclopramide
9 March 2009
Japan stock market week to Dec 10, 2007
17 December 2007
Sanofi-Aventis and Astellas to restructure JV
10 December 2007
Pozen's MT 100 approved in UK
5 December 2005
FDA sets date for review of Pozen's drug
11 July 2005
Pozen's MT 100 "not approvable"
7 June 2004
FDA rejects Pozen's lead migraine product
27 October 2003
Pozen files NDA in the USA for MT 100
11 August 2003
Baxter acquires ESI in $305M deal
6 January 2003
Pozen gets OK for rapid migraine drug dev't
12 August 2002
Pozen to file requested data on MT 100 in 2002
20 September 2001
Pozen completes Ph III program for MT 100
21 February 2001
Pozen rocked by delay to migraine drug
30 January 2001
More drugs for UK ambulance paramedics
22 November 2000
RiboGene's Pramidin launched in Italy
9 April 1999
Synthelabo full-year sales increase 7.1%
19 January 1999
Mosapride Launched
15 October 1998
RiboGene's Pramidin Approved In Italy
1 October 1998
Roberts To Develop Intranasal Emesis Drug
22 July 1998
Polish Cancer Drug Price Subsidies End
22 April 1998
OxiGene Shares Down After Sensamide Study
17 September 1997
Synthelabo Presents 1996 Highlights, New Research
21 April 1997
Russian Drug Output Fails To Meet Demand
27 January 1997
Aspirin and antiemetic versus GW's sumatriptan
16 October 1995
OxiGene: Neu-Sensamide study
18 September 1995
Synthelabo Reports On New Products
17 April 1995
Overseas Sales Lift Synthelabo Nine Month Results
14 November 1994
Roberts Rights Acquisition
12 September 1994
FRANCE BARS IMIGRAN REIMBURSEMENT?
27 June 1994
GENERIC DRUGS AND DELIVERY SYSTEMS
18 April 1994
14% SALES BOOST FOR SYNTHELABO
14 February 1994
103% NET INCOME RISE FOR ISRAEL's TEVA
22 November 1993
OXIGENE'S RADIATION SENSITIZER: PH I
22 November 1993
SYNTHELABO TAKES ON EUROPEAN DIMENSION
26 July 1993
SANDOZ' ONCE-DAILY TROPISETRON
12 July 1993
GLAXO COMPROMISES OVER ONDANSETRON PATENT
26 April 1993
SYNTHELABO RESEARCH AND DEVELOPMENT
12 April 1993
SYNTHELABO'S SALES ALMOST DOUBLE IN 1992
12 April 1993
RPSGB CANDIDATES FOR POM-TO-P SWITCHING
2 November 1992
ZOFRAN APPROVED IN UK FOR PONV
11 May 1992
POST-ELECTION OUTLOOK FOR UK HEALTH SECTOR
20 April 1992
Showing 1-45 of 45 articles
- 1
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
